Nostrum Biodiscovery is a computational drug discovery technology developer, spun off in 2016 from the Barcelona Supercomputing Center (BSC-CNS) and the Institute for Research in Biomedicine (IRB Barcelona), two of Spain’s leading international research centres.
We combine physics-based molecular modelling, high-performance computing and AI, with expert human judgment in the loop at every step. Our proprietary platforms, including PELE®, TPD-Suite®, GluePELE, PELETAC, XNAHub® and ChaRNABERT, sit alongside rigorously benchmarked third-party tools, so each project gets the best solution for its target and modality.
We are modality-agnostic. We work across small molecules and proximity inducers (molecular glues, PROTACs), proteins and peptides (antibodies, binders, vaccines, enzymes), and nucleic acids (ASOs, siRNA, aptamers, RNA vaccines). AI-native since 2018, we have tackled more than 130 targets, 30% of them considered “undruggable”.
We have delivered 220+ projects for 98 clients, half of whom come back. We partner with pharma, biotech and industry in 20+ countries, including five of the top ten global pharmaceutical companies, through fee-for-service, licensing and co-development models, from our headquarters in Barcelona and our office in Boston.
December 2015
Foundation
June 2016
NEOTEC - CDTi
July 2016
Seed capital from
Fundación Marcelino Botín
Jan 2018
1st-AI pharma project
Jan 2019
45% Revenue Generated from International Sales
December 2019
Senén Vilaró award to
the Best innovative startup
December 2020
Breakeven point
Jan 2025
80%+ of sales from international clients
September 2016
1st internal DD project
October 2016
First DD contract
December 2018
BioExcel project granted - H2020-EC
June 2019
First PCT granted for an NCE in cardiovascular therapeutic area
May 2019
Enzyme Engineering Division created
June 2019
EE first contract in Europe
August 2019
EE first contract in the USA
January 2020
First PluriZyme in the PDB
November 2020
Protein Engineering Congress EU Sponsor
May 2020
Nucleic Acids division created
June 2020
First client
May 2016
ED/MD is transferred
September 2016
PELE is transferred
February 2017
PELEplat 1.0 launch
August 2018
PELE++ success case
Paper with ESTEVE
October 2019
Protein-protein docking technology later licensed to Nostrum ranked among the best in the CASP13-CAPRI experiment
November 2019
PELE++ success case
Paper with Almirall
December 2019
PELE++ success case
Paper with Janssen Pharmaceutica
July 2020
Protein-protein docking technology is transferred to Nostrum
September 2020
PELE++ success case
Paper with Emerald
PELEplat DD/EE/AI
Marc Gómez
Project Manager
Luca Maggi
Project Manager
Jordi Martín
PhD Student
Mark Mayhew
Senior Advisor on Business Strategy
